Novo Nordisk's Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study findsMarket Watch • 11/11/23
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of MedicineGlobeNewsWire • 11/11/23
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.Market Watch • 11/10/23
Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is ApprovedForbes • 11/10/23
Novo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand productionMarket Watch • 11/10/23
The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100The Motley Fool • 11/10/23
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, DenmarkGlobeNewsWire • 11/10/23
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk BillionsThe Motley Fool • 11/09/23
Novo Holdings A/S, a subsidiary of Novo Nordisk Foundation, becomes interested party in the Tel Aviv Stock Exchange (TASE), holding 8.42% sharesPRNewsWire • 11/07/23
Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programmeGlobeNewsWire • 11/06/23
